Caribou Biosciences, Inc. (NASDAQ: CRBU - Get Free Report) has been given an average rating of "Mode

B of A Securities analyst Alec Stranahan maintains Caribou Biosciences (NASDAQ:CRBU) with a Buy a

Caribou Biosciences, Inc. (CRBU) came out with a quarterly loss of $0.24 per share versus the Zacks

Caribou Biosciences (NASDAQ:CRBU) reported quarterly losses of $(0.24) per share which beat the anal

-- ANTLER phase 1 data presented at EHA 2026 reinforce vispa-cel safety, efficacy, and durability ar

Here is how Caribou Biosciences, Inc. (CRBU) and Bioventus (BVS) have performed compared to their se

BERKELEY, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a lead

-- Single dose of CB-011 produced deep, durable responses in heavily pretreated, BCMA-naïve patients

-- Single dose of vispa-cel produced durable responses in 2L LBCL patients: 82% ORR, 67% CR rate, an

-- Single dose of CB-011 produced deep, durable responses in heavily pretreated, BCMA-naïve patients

Caribou Biosciences NASDAQ: CRBU Chief Executive Officer Rachel Haurwitz said the company is advanci

Caribou Biosciences, Inc. (CRBU) Presents at Jefferies Global Healthcare Conference 2026 Transcript

BERKELEY, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leadi

Caribou Biosciences, Inc. (CRBU) Presents at Bank of America Global Healthcare Conference 2026 Trans

BERKELEY, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leadi

Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceu

BERKELEY, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leadi

HC Wainwright & Co. analyst Robert Burns maintains Caribou Biosciences (NASDAQ:CRBU) with a B

Caribou Biosciences, Inc. (CRBU) came out with a quarterly loss of $0.26 per share versus the Zacks

Caribou Biosciences (NASDAQ:CRBU) reported quarterly losses of $(0.26) per share which beat the anal

-- Achieved alignment with FDA on pivotal ANTLER-3 trial design for vispa-cel in 2L LBCL -- -- Longe

BERKELEY, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leadi

Genomics gains momentum as breakthroughs, falling sequencing costs, and CRISPR advances drive precis

HC Wainwright & Co. analyst Robert Burns reiterates Caribou Biosciences (NASDAQ:CRBU) with a

Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmace

-- RMAT granted based on promising initial clinical data, including previously disclosed recommended

Caribou Biosciences offers the strongest allogeneic CAR-T data to date, with efficacy and safety riv

Evercore ISI Group analyst Jonathan Miller maintains Caribou Biosciences (NASDAQ:CRBU) with a Out

Caribou Biosciences (NASDAQ:CRBU) reported quarterly losses of $(0.28) per share which beat the anal

Clear Street analyst Bill Maughan initiates coverage on Caribou Biosciences (NASDAQ:CRBU) with a

Caribou Biosciences (NASDAQ:CRBU) reported quarterly losses of $(0.30) per share which beat the anal

The CNN Money Fear and Greed index showed some improvement in the overall market sentiment, but the

U.S. stocks traded higher toward the end of trading, with the S&P 500 index gaining over 1% on T

Shares of Asana, Inc. (NYSE: ASAN) fell sharply during Tuesday’s session following soft FY25 revenue

U.S. stocks traded mostly lower, with the Dow Jones falling over 20 points on Friday.

Gainers Carbon Revolution Public Limited (NASDAQ: CREV) shares jumped 396.2% to $145.49 after ga

Investors are on the hunt for undervalued, under followed and emerging stocks, and retail traders ha

  Friday's session saw 104 companies set new 52-week lows.

  During Wednesday's session, 104 stocks hit new 52-week lows.

  On Monday, 198 companies hit new 52-week lows.

Gainers Panbela Therapeutics, Inc. (NASDAQ: PBLA) shares jumped 53% to close at $0.58 on Friday.

  During Monday's trading, 1214 companies set new 52-week lows.

  On Friday, 422 stocks made new 52-week lows.

U.S. stocks traded lower this morning, with the Dow Jones dropping more than 600 points on Friday.

  During Thursday, 849 stocks hit new 52-week lows.

  Wednesday's session saw 784 companies set new 52-week lows.